- Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
- Recursion Announces Proposed Offering of Class A Common Stock
- Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
- Recursion to Participate in Upcoming Investor Conferences
- Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
- Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
- Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
- Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
- Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
- Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
More ▼
Key statistics
On Friday, Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 8.35, 68.01% above the 52 week low of 4.97 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.25 |
---|---|
High | 8.49 |
Low | 8.14 |
Bid | 8.28 |
Offer | 8.40 |
Previous close | 8.05 |
Average volume | 4.14m |
---|---|
Shares outstanding | 272.89m |
Free float | 253.54m |
P/E (TTM) | -- |
Market cap | 2.28bn USD |
EPS (TTM) | -1.62 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 21:00 BST.
More ▼